To avoid potential toxicity, the content of all vitamin preparations, particularly vitamin A, should be considered when used together with other supplements.
Vitamins A and D
Vitamins A and D (vitamin A 4000unit/vitamin D 400unit) capsules BPC 1973
Vitamin A palmitate
Retinol 50,000units/ml solution for injection vials (Unlicensed, Imported)
Section Title (top level)
Section Title (sub level)
First Choice item
Non Formulary section
Display tracking information
Link to adult BNF
Link to children's BNF
Link to SPCs
Scottish Medicines Consortium
High Cost Medicine
Cancer Drugs Fund
High Cost Drug Approval System
Traffic Light Status Information
Medicines that can only be prescribed within Secondary Care.
Examples of medicines which fall into this category are:
Certain new medicines and new indications for older medicines where there is at present
no experience of use in Primary Care.
Medicines or dressings not available or prescribable in Primary Care.
Where a medicine has been classified as Amber E, but an approved shared-care guideline is not yet available
Medicines which can be prescribed within Secondary Care, but are only suitable for prescribing in Primary Care after specialist referral. There is no need for approved shared care guidelines for medicines in this category. This replaces Amber 2 on the North Staffs Formulary.
Medicines which can be prescribed within Secondary Care, but are only considered suitable for prescribing in Primary Care under an approved shared-care agreement (ESCA) or Rationale for Initiation, Continuation and Discontinuation (RICaD). This replaces Amber 1 on the North Staffs Formulary
Medicines which can be prescribed in either Primary or Secondary Care.
These medicines have been reviewed by the New Medicines Committee and the Area Prescribing Committee and found not to be suitable for inclusion in the Joint Formulary.
Inadequate or weak evidence for efficacy
No clearly defined local need
Lack of long term safety data
No perceived benefit over established formulary alternatives
Prescribers can consider these medicines where formulary alternatives are unsuitable, ineffective or